Food and Drug Administration
Pulmonary-Allergy Drugs Advisory Committee
September 6, 2002
Slides
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Introduction and overview, Dr. Burkhard Blank, MD, Boehringer Ingelheim Pharmaceuticals, Inc. htm ppt
Spiriva® (tiotropium bromide) Inhalation Powder, Dr. Lisa Kammerman, PhD, FDA htm ppt
Spiriva® (tiotropium bromide) Inhalation Powder, Dr. Eugene Sullivan, MD FCCP, FDA htm ppt
Questions for the Committee htm ppt
Open Public Hearing
Public Comments pdf